Opko Health issues additional $125 million senior secured notes backed by mazdutide royalties
OPK•Expanded royalty-backed financing
Opko Health issued $125 million of senior secured notes in an expanded financing with HealthCare Royalty, a KKR business.
The notes are secured by royalty interests tied to Opko’s mazdutide license with Eli Lilly.
The maturity is set for 2044, matching Opko’s existing HealthCare Royalty notes under the original arrangement.
Payments under the expanded structure are capped at 1.5x the funded amount, with future royalty economics reverting to Opko thereafter.
